Ammonium Chloride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ammonium Chloride: From Expectorant Use to Acute Laryngopharyngitis
One-Sentence Summary
Ammonium chloride is a classical expectorant. In South Africa it is registered in cough syrups and one tablet product, but the registration records give no indication text. The TxGNN model predicts it may be effective for acute laryngopharyngitis, with a very high score. However, there are 0 clinical trials and 0 publications for this indication, so the prediction is a model prior and not evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in SAHPRA records. Product names (e.g. Benylin & codeine, Expectalin with cod) suggest cough/expectorant use. |
| Predicted New Indication | Acute laryngopharyngitis |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 18 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Ammonium chloride is a classical expectorant, and it may act on mucosal secretions. Mechanistically, it may be applicable to inflammation of the throat and upper airway.
A plausible mucosal and secretion-related rationale therefore exists. It is only a prior. The score is high, but no trial or publication tests ammonium chloride in acute laryngopharyngitis. The link should not be treated as established.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Showing 5 of 18 registrations. The registration records do not include approved indication text.
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| G830 (ACT101/1965) | Benylin & codeine | Syrup | Not stated in record |
| 31/2.6/0241 | Coprax | Tablet | Not stated in record |
| 28/10.1/0249 | Expectalin with cod | Syrup | Not stated in record |
| 27/10.1/0529 | Dynalex | Syrup | Not stated in record |
| G/10.1/1112 | Broncleer & cod unboxed | Syrup | Not stated in record |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there is no clinical trial, no literature and no mechanism data for acute laryngopharyngitis (L5, model prediction only). Safety information from the SAHPRA PI is also missing, so the candidate cannot yet pass safety screening.
Among the other predicted indications, only headache disorder has drug-specific human reports. These are five uncontrolled historical reports from 1955 to 1982 on chronic migraine and headache, with no modern replication. This is worth a separate research question, but it is not a basis for clinical use.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications (download and parse the PI PDF)
- Approved indication text for the registered products
- Mechanism of action data (DrugBank)
- Any clinical or observational evidence in acute laryngopharyngitis
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.